LGM
Logos Global Management Portfolio holdings
AUM
$749M
This Quarter Return
-5.41%
1 Year Return
+18.94%
3 Year Return
+431.72%
5 Year Return
+481.1%
10 Year Return
–
AUM
$868M
AUM Growth
+$868M
(-8.7%)
Cap. Flow
+$19M
Cap. Flow
% of AUM
2.19%
Top 10 Holdings %
Top 10 Hldgs %
50.33%
Holding
70
New
16
Increased
12
Reduced
15
Closed
15
Top Buys
| 1 |
argenx
ARGX
|
$58.1M |
| 2 |
Merus
MRUS
|
$50.3M |
| 3 |
Revolution Medicines
RVMD
|
$46.6M |
| 4 |
Disc Medicine
IRON
|
$41.7M |
| 5 |
MoonLake Immunotherapeutics
MLTX
|
$33M |
Top Sells
| 1 |
Immunocore
IMCR
|
$58.5M |
| 2 |
Dyne Therapeutics
DYN
|
$51.7M |
| 3 |
Sarepta Therapeutics
SRPT
|
$39.5M |
| 4 |
Immunovant
IMVT
|
$31.7M |
| 5 |
Geron
GERN
|
$29.7M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
IDEAYA Biosciences
IDYA
$2.15B
| $59.7M | 4.8% | 1,700,000 +200,000 | +13% | +$7.02M |
|
|
2
argenx
ARGX
$43.6B
| $58.1M | 4.67% | +135,000 | New | +$58.1M |
|
|
3
Merus
MRUS
$4.98B
| $50.3M | 4.05% | +850,000 | New | +$50.3M |
|
|
4
Revolution Medicines
RVMD
$7.1B
| $46.6M | 3.75% | +1,200,000 | New | +$46.6M |
|
5
Structure Therapeutics
GPCR
$1.11B
| $43.2M | 3.47% | 1,100,000 +379,942 | +53% | +$14.9M |
|
|
6
Disc Medicine
IRON
$2.07B
| $41.7M | 3.35% | +925,000 | New | +$41.7M |
|
7
Ocular Therapeutix
OCUL
$2.12B
| $35.2M | 2.83% | 5,150,000 -661,436 | -11% | -$4.52M |
|
8
Olema Pharmaceuticals
OLMA
$375M
| $34.7M | 2.79% | 3,208,875 -1,175,000 | -27% | -$12.7M |
|
9
Vera Therapeutics
VERA
$1.38B
| $34.4M | 2.76% | 950,000 +375,000 | +65% | +$13.6M |
|
|
10
MoonLake Immunotherapeutics
MLTX
$3.54B
| $33M | 2.65% | +750,000 | New | +$33M |
|
11
Janux Therapeutics
JANX
$1.37B
| $31.4M | 2.53% | 750,000 +600,000 | +400% | +$25.1M |
|
12
Xencor
XNCR
$580M
| $28.4M | 2.28% | 1,500,000 +850,000 | +131% | +$16.1M |
|
|
SLN
13
Silence Therapeutics
SLN
$227M
| $28M | 2.26% | 1,476,061 | – | – |
|
|
14
Sarepta Therapeutics
SRPT
$1.78B
| $23.7M | 1.91% | 150,000 -250,000 | -63% | -$39.5M |
|
15
Akero Therapeutics
AKRO
$3.74B
| $18.8M | 1.51% | 800,000 | – | – |
|
16
Design Therapeutics
DSGN
$315M
| $16.9M | 1.36% | 5,032,501 | – | – |
|
17
Annexon
ANNX
$226M
| $16.2M | 1.3% | 3,300,000 +250,000 | +8% | +$1.23M |
|
18
Apellis Pharmaceuticals
APLS
$3.48B
| $15.3M | 1.23% | 400,000 -400,000 | -50% | -$15.3M |
|
|
19
Immunovant
IMVT
$2.56B
| $15.2M | 1.22% | 575,000 -1,200,000 | -68% | -$31.7M |
|
20
Nuvalent
NUVL
$5.52B
| $14.8M | 1.19% | +195,000 | New | +$14.8M |
|
21
Xenon Pharmaceuticals
XENE
$2.98B
| $14.6M | 1.18% | +375,000 | New | +$14.6M |
|
22
Ionis Pharmaceuticals
IONS
$6.8B
| $14.3M | 1.15% | +300,000 | New | +$14.3M |
|
23
Stoke Therapeutics
STOK
$1.08B
| $14.2M | 1.14% | +1,050,000 | New | +$14.2M |
|
24
Erasca
ERAS
$445M
| $13.9M | 1.12% | +5,900,000 | New | +$13.9M |
|
25
Enliven Therapeutics
ELVN
$1.2B
| $13.9M | 1.12% | 595,000 -979,220 | -62% | -$22.9M |
|